VAMAS6
MCID: VTL009
MIFTS: 42

Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6 (VAMAS6)

Categories: Genetic diseases, Immune diseases, Rare diseases, Skin diseases

Aliases & Classifications for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

MalaCards integrated aliases for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6:

Name: Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6 56 13
Generalized Vitiligo 73 71
Vitiligo 73 71
Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1 71
Vamas6 56
Vtlg 73

Characteristics:

OMIM:

56
Inheritance:
? epistatically interacting multiple autosomal recessive


HPO:

31
vitiligo-associated multiple autoimmune disease susceptibility 6:
Inheritance autosomal recessive inheritance


Classifications:



External Ids:

OMIM 56 193200
MeSH 43 D014820
UMLS 71 C0042900 C1304470 C1847835

Summaries for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

UniProtKB/Swiss-Prot : 73 Vitiligo: A pigmentary disorder of the skin and mucous membranes. It is characterized by circumscribed depigmented macules and patches, commonly on extensor aspects of extremities, on the face or neck and in skin folds. Vitiligo is a progressive disorder in which some or all of the melanocytes in the affected skin are selectively destroyed. It is a multifactorial disorder with a complex etiology probably including autoimmune mechanisms, and is associated with an elevated risk of other autoimmune diseases.

MalaCards based summary : Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6, also known as generalized vitiligo, is related to vitiligo-associated multiple autoimmune disease susceptibility 1 and deafness, congenital, with vitiligo and achalasia, and has symptoms including pruritus and exanthema. An important gene associated with Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6 is PTPN22 (Protein Tyrosine Phosphatase Non-Receptor Type 22). The drugs Pimecrolimus and mometasone furoate have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and thyroid, and related phenotypes are vitiligo and nevus

More information from OMIM: 193200

Related Diseases for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Diseases in the Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 1 family:

Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Diseases related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6 via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 612, show less)
# Related Disease Score Top Affiliating Genes
1 vitiligo-associated multiple autoimmune disease susceptibility 1 13.1
2 deafness, congenital, with vitiligo and achalasia 12.6
3 alopecia universalis onychodystrophy vitiligo 12.4
4 vitiligo, progressive, with mental retardation and urethral duplication 12.3
5 spastic paraplegia 23, autosomal recessive 12.2
6 autoimmune disease 1 12.1
7 alopecia areata 11.8
8 alezzandrini syndrome 11.7
9 autoimmune disease 2 11.6
10 autoimmune disease 3 11.6
11 autoimmune disease 4 11.6
12 schrander-stumpel theunissen hulsmans syndrome 11.6
13 vogt-koyanagi-harada disease 11.6
14 autoimmune polyendocrine syndrome, type i, with or without reversible metaphyseal dysplasia 11.6
15 autoimmune polyglandular syndrome type 3 11.6
16 halo nevus 11.5
17 hypoadrenocorticism, familial 11.4
18 hemifacial atrophy, progressive 11.4
19 autoimmune atrophic gastritis 11.4
20 stiff-person syndrome 11.3
21 familial cold autoinflammatory syndrome 3 11.3
22 hereditary spastic paraplegia 23 11.2
23 ermine phenotype 11.1
24 combined cellular and humoral immune defects with granulomas 11.1
25 nijmegen breakage syndrome 11.1
26 lelis syndrome 11.1
27 t-cell receptor-alpha/beta deficiency 11.1
28 hypopigmentation of eyelid 11.1
29 gemignani syndrome 11.1
30 pigmentation anomaly of the skin 11.1
31 autoimmune disease 10.9
32 skin disease 10.8
33 alopecia 10.8
34 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.7
35 psoriasis 10.7
36 pustulosis of palm and sole 10.7
37 melanoma 10.7
38 melanoma, cutaneous malignant 10 10.6
39 thyroiditis 10.6
40 hypothyroidism 10.6
41 dowling-degos disease 1 10.5
42 dermatitis 10.5
43 dermatitis, atopic 10.5
44 skin carcinoma 10.5
45 hashimoto thyroiditis 10.4
46 halo nevi 10.4
47 lichen planus 10.4
48 thyroid gland disease 10.4
49 pernicious anemia 10.4
50 graves' disease 10.4
51 uveitis 10.4
52 systemic scleroderma 10.3
53 keratosis 10.3
54 lupus erythematosus 10.3
55 myasthenia gravis 10.3
56 urticaria 10.3
57 microphthalmia 10.3
58 localized scleroderma 10.3
59 mycosis fungoides 10.3
60 hansen's disease 10.3
61 leprosy 3 10.3
62 piebald trait 10.2
63 alopecia universalis congenita 10.2
64 contact dermatitis 10.2
65 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 10.2
66 hyperthyroidism 10.2
67 anemia, x-linked, with or without neutropenia and/or platelet abnormalities 10.2
68 deficiency anemia 10.2
69 neurofibromatosis, type ii 10.2
70 immune deficiency disease 10.2
71 basal cell carcinoma 10.2
72 ulcerative colitis 10.2
73 skin melanoma 10.2
74 celiac disease 1 10.2
75 retinitis pigmentosa 10.2
76 dermatitis herpetiformis, familial 10.2
77 neuroretinitis 10.2
78 rickets 10.2
79 retinitis 10.2
80 dermatitis herpetiformis 10.2
81 bullous pemphigoid 10.2
82 pemphigus 10.2
83 albinism 10.2
84 cytokine deficiency 10.2
85 hypomelanotic disorder 10.2
86 rapidly involuting congenital hemangioma 10.2
87 discoid lupus erythematosus 10.2
88 ige responsiveness, atopic 10.1
89 lichen sclerosus et atrophicus 10.1
90 squamous cell carcinoma 10.1
91 hepatitis c 10.1
92 liver cirrhosis 10.1
93 diabetes mellitus 10.1
94 47,xyy 10.1
95 spondyloarthropathy 1 10.1
96 rheumatoid arthritis 10.1
97 graft-versus-host disease 10.1
98 inflammatory spondylopathy 10.1
99 telangiectasis 10.1
100 gastritis 10.1
101 spondylitis 10.1
102 actinic keratosis 10.1
103 pemphigus vulgaris, familial 10.1
104 cutaneous t cell lymphoma 10.1
105 colitis 10.1
106 primary biliary cirrhosis 10.1
107 retinal degeneration 10.1
108 neurofibromatosis 10.1
109 sarcoidosis 1 10.1
110 intraocular pressure quantitative trait locus 10.1
111 inflammatory bowel disease 10.1
112 pigmentation disease 10.1
113 goiter 10.1
114 candidiasis 10.1
115 allergic contact dermatitis 10.1
116 crohn's disease 10.1
117 lentigines 10.0
118 retinal detachment 10.0
119 scleroderma, familial progressive 10.0
120 yemenite deaf-blind hypopigmentation syndrome 10.0
121 exanthem 10.0
122 sensorineural hearing loss 10.0
123 anogenital venereal wart 10.0
124 hypoparathyroidism 10.0
125 porphyria 10.0
126 skin atrophy 10.0
127 purpura 10.0
128 vasculitis 10.0
129 kaposi sarcoma 10.0
130 anemia, autoimmune hemolytic 10.0
131 cutaneous lupus erythematosus 10.0
132 allergic hypersensitivity disease 10.0
133 hemolytic anemia 10.0
134 atrophic gastritis 10.0
135 48,xyyy 10.0
136 frontal fibrosing alopecia 10.0
137 acanthosis nigricans 10.0
138 multiple sclerosis 10.0
139 systemic lupus erythematosus 10.0
140 nail disorder, nonsyndromic congenital, 1 10.0
141 hypomelanosis of ito 10.0
142 hepatitis c virus 10.0
143 sexual disorder 10.0
144 open-angle glaucoma 10.0
145 thrombocytopenia 10.0
146 ichthyosis 10.0
147 viral hepatitis 10.0
148 hepatitis b 10.0
149 autoimmune hepatitis 10.0
150 epidermolysis bullosa 10.0
151 adenocarcinoma 10.0
152 syphilis 10.0
153 hypertrichosis 10.0
154 amelanotic melanoma 10.0
155 acquired immunodeficiency syndrome 10.0
156 cataract 10.0
157 arthritis 10.0
158 encephalitis 10.0
159 keloid disorder 10.0
160 alopecia totalis 10.0
161 chronic graft versus host disease 10.0
162 dilution, pigmentary 9.9
163 glaucoma, primary open angle 9.9
164 renal cell carcinoma, nonpapillary 9.9
165 pityriasis rubra pilaris 9.9
166 porphyria cutanea tarda 9.9
167 eosinophilic fasciitis 9.9
168 sjogren syndrome 9.9
169 thymoma, familial 9.9
170 graves disease 1 9.9
171 helicobacter pylori infection 9.9
172 branchiootic syndrome 1 9.9
173 macular degeneration, age-related, 1 9.9
174 psoriatic arthritis 9.9
175 anxiety 9.9
176 leukemia, acute lymphoblastic 3 9.9
177 immunoglobulin alpha deficiency 9.9
178 hereditary lymphedema i 9.9
179 lepromatous leprosy 9.9
180 sarcoma 9.9
181 choroiditis 9.9
182 polycystic ovary syndrome 9.9
183 common variable immunodeficiency 9.9
184 tuberous sclerosis 9.9
185 gonadal dysgenesis 9.9
186 cholera 9.9
187 hepatitis 9.9
188 keratoacanthoma 9.9
189 thymoma 9.9
190 vaccinia 9.9
191 neurodermatitis 9.9
192 mammary paget's disease 9.9
193 spindle cell sarcoma 9.9
194 connective tissue disease 9.9
195 adenoma 9.9
196 herpes zoster 9.9
197 myeloid leukemia 9.9
198 molluscum contagiosum 9.9
199 fasciitis 9.9
200 hypereosinophilic syndrome 9.9
201 polymyositis 9.9
202 depression 9.9
203 posttransplant acute limbic encephalitis 9.9
204 inflammatory myopathy with abundant macrophages 9.9
205 onychomatricoma 9.9
206 thyroid carcinoma 9.9
207 alopecia areata 1 9.8
208 cleft palate, isolated 9.8
209 immunoglobulin a deficiency 1 9.8
210 keloid formation 9.8
211 melanoma, uveal 9.8
212 ocular cicatricial pemphigoid 9.8
213 syringomyelia, noncommunicating isolated 9.8
214 albinism, oculocutaneous, type ii 9.8
215 lung cancer 9.8
216 hemochromatosis, type 1 9.8
217 phenylketonuria 9.8
218 taqi polymorphism 9.8
219 ataxia and polyneuropathy, adult-onset 9.8
220 homocysteinemia 9.8
221 myocardial infarction 9.8
222 lung cancer susceptibility 3 9.8
223 premature ovarian failure 7 9.8
224 leukemia, acute lymphoblastic 9.8
225 chronic ulcer of skin 9.8
226 autoimmune gastritis 9.8
227 erythema multiforme 9.8
228 oculocutaneous albinism 9.8
229 vitamin b12 deficiency 9.8
230 alexithymia 9.8
231 crohn's colitis 9.8
232 bone disease 9.8
233 dermatomyositis 9.8
234 tonsillitis 9.8
235 pre-eclampsia 9.8
236 social phobia 9.8
237 erysipelas 9.8
238 hemopericardium 9.8
239 pericardial effusion 9.8
240 nephrotic syndrome 9.8
241 eclampsia 9.8
242 autoimmune polyendocrine syndrome 9.8
243 disease of mental health 9.8
244 panniculitis 9.8
245 facial hemiatrophy 9.8
246 hypogonadism 9.8
247 hidradenitis suppurativa 9.8
248 hidradenitis 9.8
249 agammaglobulinemia 9.8
250 papilloma 9.8
251 kidney cancer 9.8
252 transitional cell carcinoma 9.8
253 lipid metabolism disorder 9.8
254 neurilemmoma 9.8
255 syringomyelia 9.8
256 porokeratosis 9.8
257 myopathy 9.8
258 superficial basal cell carcinoma 9.8
259 adjustment disorder 9.8
260 dystonia 9.8
261 lymphopenia 9.8
262 scabies 9.8
263 night blindness 9.8
264 herpes simplex 9.8
265 lichen nitidus 9.8
266 chickenpox 9.8
267 waardenburg's syndrome 9.8
268 homocystinuria 9.8
269 iridocyclitis 9.8
270 neurofibroma 9.8
271 hyperphenylalaninemia 9.8
272 mitochondrial disorders 9.8
273 drug reaction with eosinophilia and systemic symptoms 9.8
274 glioma 9.8
275 guttate psoriasis 9.8
276 homologous wasting disease 9.8
277 ichthyosis, acquired 9.8
278 linear scleroderma 9.8
279 oral lichen planus 9.8
280 prurigo nodularis 9.8
281 splenomegaly 9.8
282 tièche-jadassohn nevus 9.8
283 cytomegalovirus infection 9.8
284 glial tumor 9.8
285 premature aging 9.8
286 polyendocrinopathy 9.8
287 atrial standstill 1 9.6
288 bladder cancer 9.6
289 breast cancer 9.6
290 colorectal cancer 9.6
291 hepatocellular carcinoma 9.6
292 coloboma of macula 9.6
293 epidermoid cysts 9.6
294 esophageal cancer 9.6
295 external auditory canal, bilateral atresia of, with congenital vertical talus 9.6
296 coffin-siris syndrome 1 9.6
297 attention deficit-hyperactivity disorder 9.6
298 hypertelorism 9.6
299 hypertension, essential 9.6
300 hypertriglyceridemia, familial 9.6
301 ichthyosis vulgaris 9.6
302 kabuki syndrome 1 9.6
303 keratitis, hereditary 9.6
304 lipomatosis, multiple 9.6
305 melanoma, cutaneous malignant 1 9.6
306 migraine with or without aura 1 9.6
307 facioscapulohumeral muscular dystrophy 1 9.6
308 myositis 9.6
309 neurofibromatosis, type i 9.6
310 nevus anemicus 9.6
311 noonan syndrome 1 9.6
312 obsessive-compulsive disorder 9.6
313 optic atrophy 1 9.6
314 ovarian cancer 9.6
315 mccune-albright syndrome 9.6
316 polyposis, skin pigmentation, alopecia, and fingernail changes 9.6
317 porokeratosis 1, multiple types 9.6
318 hutchinson-gilford progeria syndrome 9.6
319 retinoblastoma 9.6
320 small cell cancer of the lung 9.6
321 temporal arteritis 9.6
322 thrombocytopenic purpura, autoimmune 9.6
323 trichomegaly 9.6
324 trigeminal neuralgia 9.6
325 down syndrome 9.6
326 acrodermatitis enteropathica, zinc-deficiency type 9.6
327 acyl-coa dehydrogenase, short-chain, deficiency of 9.6
328 alkaptonuria 9.6
329 chiari malformation type ii 9.6
330 right atrial isomerism 9.6
331 ataxia-telangiectasia 9.6
332 complement component 2 deficiency 9.6
333 epidermodysplasia verruciformis 1 9.6
334 fanconi anemia, complementation group a 9.6
335 hydatidiform mole, recurrent, 1 9.6
336 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 9.6
337 moyamoya disease 1 9.6
338 myxedema 9.6
339 3-methylglutaconic aciduria, type iii 9.6
340 adrenoleukodystrophy 9.6
341 body mass index quantitative trait locus 11 9.6
342 bazex syndrome 9.6
343 incontinentia pigmenti 9.6
344 kearns-sayre syndrome 9.6
345 mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes 9.6
346 diabetes mellitus, insulin-dependent, 8 9.6
347 cd4/cd8 t-cell ratio 9.6
348 suppression of tumorigenicity 12 9.6
349 leukemia, acute myeloid 9.6
350 body mass index quantitative trait locus 9 9.6
351 body mass index quantitative trait locus 8 9.6
352 psoriasis 4 9.6
353 psoriasis 7 9.6
354 nasopharyngeal carcinoma 9.6
355 allergic rhinitis 9.6
356 body mass index quantitative trait locus 4 9.6
357 body mass index quantitative trait locus 10 9.6
358 mycobacterium tuberculosis 1 9.6
359 kala-azar 1 9.6
360 leukemia, chronic myeloid 9.6
361 body mass index quantitative trait locus 7 9.6
362 major depressive disorder 9.6
363 human immunodeficiency virus type 1 9.6
364 chilblain lupus 1 9.6
365 kawasaki disease 9.6
366 body mass index quantitative trait locus 12 9.6
367 psoriasis 10 9.6
368 body mass index quantitative trait locus 14 9.6
369 hearing loss, noise-induced 9.6
370 cholangitis, primary sclerosing 9.6
371 cyanosis, transient neonatal 9.6
372 acatalasemia 9.6
373 microcephaly, epilepsy, and diabetes syndrome 9.6
374 myelodysplastic syndrome 9.6
375 retinal dystrophy, iris coloboma, and comedogenic acne syndrome 9.6
376 body mass index quantitative trait locus 18 9.6
377 cholangiocarcinoma 9.6
378 helix syndrome 9.6
379 body mass index quantitative trait locus 19 9.6
380 body mass index quantitative trait locus 20 9.6
381 hypertrophic scars 9.6
382 chikungunya 9.6
383 superficial mycosis 9.6
384 multinodular goiter 9.6
385 variola major 9.6
386 adult t-cell leukemia 9.6
387 ocular albinism 9.6
388 autosomal recessive disease 9.6
389 androgenic alopecia 9.6
390 chronic venous insufficiency 9.6
391 mucosal melanoma 9.6
392 diffuse alopecia areata 9.6
393 ptosis 9.6
394 porencephaly 9.6
395 lymphoproliferative syndrome 9.6
396 physical disorder 9.6
397 fibrous dysplasia 9.6
398 chronic myelomonocytic leukemia 9.6
399 middle east respiratory syndrome 9.6
400 hypogonadotropic hypogonadism 9.6
401 venous insufficiency 9.6
402 dry eye syndrome 9.6
403 pleomorphic lipoma 9.6
404 pleurisy 9.6
405 tuberculoid leprosy 9.6
406 glucose intolerance 9.6
407 pituitary apoplexy 9.6
408 heart disease 9.6
409 palindromic rheumatism 9.6
410 dysgammaglobulinemia 9.6
411 gestational diabetes 9.6
412 visual epilepsy 9.6
413 panuveitis 9.6
414 dysthymic disorder 9.6
415 otosclerosis 9.6
416 leukemia 9.6
417 secondary hyperparathyroidism 9.6
418 vestibular neuronitis 9.6
419 multiple epiphyseal dysplasia 9.6
420 guillain-barre syndrome 9.6
421 dilated cardiomyopathy 9.6
422 conduct disorder 9.6
423 branch retinal artery occlusion 9.6
424 central retinal artery occlusion 9.6
425 exophthalmic ophthalmoplegia 9.6
426 diarrhea 9.6
427 cutaneous porphyria 9.6
428 color blindness 9.6
429 skin sarcoidosis 9.6
430 balanitis xerotica obliterans 9.6
431 osteopetrosis 9.6
432 hyperparathyroidism 9.6
433 optic disk drusen 9.6
434 cholestasis 9.6
435 polyneuropathy 9.6
436 facial paralysis 9.6
437 benign paroxysmal positional nystagmus 9.6
438 alcoholic liver cirrhosis 9.6
439 bipolar i disorder 9.6
440 iritis 9.6
441 sclerosing cholangitis 9.6
442 primary hypertrophic osteoarthropathy 9.6
443 personality disorder 9.6
444 chromoblastomycosis 9.6
445 fungal infectious disease 9.6
446 limited scleroderma 9.6
447 mental depression 9.6
448 ocular melanoma 9.6
449 cheilitis 9.6
450 vascular disease 9.6
451 neuritis 9.6
452 calcinosis 9.6
453 telogen effluvium 9.6
454 enthesopathy 9.6
455 drug-induced hepatitis 9.6
456 chronic mucocutaneous candidiasis 9.6
457 syringoma 9.6
458 constipation 9.6
459 dental caries 9.6
460 keratopathy 9.6
461 gastroenteritis 9.6
462 iron metabolism disease 9.6
463 relapsing-remitting multiple sclerosis 9.6
464 granular cell tumor 9.6
465 acromegaly 9.6
466 gastric antral vascular ectasia 9.6
467 hemangioma 9.6
468 larynx cancer 9.6
469 acrodermatitis 9.6
470 iga glomerulonephritis 9.6
471 acute kidney failure 9.6
472 thoracic outlet syndrome 9.6
473 multiple endocrine neoplasia 9.6
474 myelitis 9.6
475 rhabdomyosarcoma 9.6
476 ischemia 9.6
477 thymic carcinoma 9.6
478 mood disorder 9.6
479 necrobiosis lipoidica 9.6
480 turner syndrome 9.6
481 mastocytosis 9.6
482 gestational trophoblastic neoplasm 9.6
483 lactic acidosis 9.6
484 plexopathy 9.6
485 pulmonary fibrosis 9.6
486 granuloma annulare 9.6
487 arthropathy 9.6
488 pituitary adenoma 9.6
489 lynch syndrome 9.6
490 liver disease 9.6
491 mutism 9.6
492 nodular basal cell carcinoma 9.6
493 infiltrative basal cell carcinoma 9.6
494 polyradiculoneuropathy 9.6
495 epidermolysis bullosa acquisita 9.6
496 erdheim-chester disease 9.6
497 spongiotic dermatitis 9.6
498 phototoxic dermatitis 9.6
499 folliculitis 9.6
500 clear cell renal cell carcinoma 9.6
501 rhinitis 9.6
502 epidermolysis bullosa simplex 9.6
503 familial retinoblastoma 9.6
504 intrahepatic cholangiocarcinoma 9.6
505 epidermolysis bullosa dystrophica 9.6
506 chronic inflammatory demyelinating polyradiculoneuropathy 9.6
507 demyelinating polyneuropathy 9.6
508 infertility 9.6
509 central nervous system vasculitis 9.6
510 sleep disorder 9.6
511 eye disease 9.6
512 malignant peripheral nerve sheath tumor 9.6
513 congestive heart failure 9.6
514 reactive arthritis 9.6
515 fibromyalgia 9.6
516 acral lentiginous melanoma 9.6
517 malignant choroid melanoma 9.6
518 viral encephalitis 9.6
519 juvenile rheumatoid arthritis 9.6
520 t-cell lymphoblastic leukemia/lymphoma 9.6
521 monoclonal gammopathy of uncertain significance 9.6
522 peptic ulcer disease 9.6
523 muscular atrophy 9.6
524 neuroblastoma 9.6
525 placenta disease 9.6
526 myocarditis 9.6
527 pellagra 9.6
528 influenza 9.6
529 retinal artery occlusion 9.6
530 fundus dystrophy 9.6
531 smallpox 9.6
532 seborrheic dermatitis 9.6
533 parasitic helminthiasis infectious disease 9.6
534 chorioretinitis 9.6
535 mitochondrial encephalomyopathy 9.6
536 dermatophytosis 9.6
537 evans' syndrome 9.6
538 pityriasis versicolor 9.6
539 leishmaniasis 9.6
540 parapsoriasis 9.6
541 cutaneous leishmaniasis 9.6
542 amyloidosis 9.6
543 achalasia 9.6
544 cleft lip 9.6
545 keratoconjunctivitis 9.6
546 orbital plasma cell granuloma 9.6
547 exophthalmos 9.6
548 cholangitis 9.6
549 pulmonary embolism 9.6
550 bronchiectasis 9.6
551 diabetic neuropathy 9.6
552 muscular dystrophy 9.6
553 carotenemia 9.6
554 limb-girdle muscular dystrophy 9.6
555 sickle cell disease 9.6
556 acquired hemophilia 9.6
557 adrenomyeloneuropathy 9.6
558 adverse events of 5-alpha-reductase inhibitors 9.6
559 autoimmune encephalitis 9.6
560 autoimmune oophoritis 9.6
561 chiari malformation 9.6
562 crystal arthropathies 9.6
563 duplication of urethra 9.6
564 encephalocele 9.6
565 enteropathica 9.6
566 exfoliative dermatitis 9.6
567 giant cell myocarditis 9.6
568 hair-an syndrome 9.6
569 herpes zoster ophthalmicus 9.6
570 lentigo maligna melanoma 9.6
571 leukemia, t-cell, chronic 9.6
572 lichen planus pigmentosus 9.6
573 meningoencephalocele 9.6
574 mitochondrial encephalomyopathy lactic acidosis and stroke-like episodes 9.6
575 multifocal choroiditis 9.6
576 necrobiotic xanthogranuloma 9.6
577 phacomatosis pigmentovascularis 9.6
578 pseudo-turner syndrome 9.6
579 pustular psoriasis 9.6
580 rasmussen johnsen thomsen syndrome 9.6
581 spastic paraparesis 9.6
582 transverse myelitis 9.6
583 vernal keratoconjunctivitis 9.6
584 autoimmune addison disease 9.6
585 color vision deficiency 9.6
586 autonomic dysfunction 9.6
587 dysphagia 9.6
588 encephalopathy 9.6
589 paraneoplastic syndromes 9.6
590 seizure disorder 9.6
591 spasticity 9.6
592 chronic cutaneous lupus erythematosus 9.6
593 primary cutaneous t-cell lymphoma 9.6
594 systemic autoimmune disease 9.6
595 cerebrofacial arteriovenous metameric syndrome 9.6
596 epidermolysis bullosa simplex with anodontia/hypodontia 9.6
597 nevus of ota 9.6
598 periodic paralysis 9.6
599 specific language disorder 9.6
600 autoimmune polyendocrinopathy type 3 9.6
601 chronic actinic dermatitis 9.6
602 rasmussen subacute encephalitis 9.6
603 idiopathic panuveitis 9.6
604 generalized eruptive keratoacanthoma 9.6
605 argyria 9.6
606 inherited retinal disorder 9.6
607 hypopigmentation of the skin 9.6
608 hyperpigmentation of the skin 9.6
609 pemphigus erythematosus 9.6
610 solar urticaria 9.6
611 primary adrenal insufficiency 9.6
612 precursor t-cell acute lymphoblastic leukemia 9.6

Graphical network of the top 20 diseases related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6:



Diseases related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Symptoms & Phenotypes for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Human phenotypes related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6:

31 (showing 2, show less)
# Description HPO Frequency HPO Source Accession
1 vitiligo 31 HP:0001045
2 nevus 31 HP:0003764

Symptoms via clinical synopsis from OMIM:

56
Skin:
vitiligo
halo nevi

Misc:
onset after birth
no predilection for ventral skin

Clinical features from OMIM:

193200

UMLS symptoms related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6:


pruritus, exanthema

Drugs & Therapeutics for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Drugs for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 116, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pimecrolimus Approved, Investigational Phase 4 137071-32-0 17753757 6447131
2
mometasone furoate Approved, Investigational, Vet_approved Phase 4 83919-23-7
3
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
4
Tretinoin Approved, Investigational, Nutraceutical Phase 4 302-79-4 444795 5538
5 Furocoumarins Phase 4
6 abobotulinumtoxinA Phase 4
7 Cholinergic Agents Phase 4
8 Botulinum Toxins Phase 4
9 Botulinum Toxins, Type A Phase 4
10 Neurotransmitter Agents Phase 4
11
Hyaluronic acid Approved, Vet_approved Phase 3 9004-61-9 53477741
12
Zinc Approved, Investigational Phase 3 7440-66-6 32051
13
Zinc sulfate Approved, Investigational Phase 3 7733-02-0
14
Latanoprost Approved, Investigational Phase 2, Phase 3 130209-82-4 5311221 5282380
15
Tacrolimus Approved, Investigational Phase 2, Phase 3 104987-11-3 445643 439492 6473866
16
Triamcinolone Approved, Vet_approved Phase 2, Phase 3 124-94-7 31307
17 Anesthetics Phase 2, Phase 3
18 Dermatologic Agents Phase 3
19 Insulin, Globin Zinc Phase 3
20 insulin Phase 3
21 Immunosuppressive Agents Phase 2, Phase 3
22 Immunologic Factors Phase 2, Phase 3
23 Calcineurin Inhibitors Phase 2, Phase 3
24 Hormones Phase 2, Phase 3
25 Hormone Antagonists Phase 2, Phase 3
26 glucocorticoids Phase 2, Phase 3
27 triamcinolone acetonide Phase 2, Phase 3
28 Triamcinolone diacetate Phase 2, Phase 3
29 Triamcinolone hexacetonide Phase 2, Phase 3
30
Hydrocortisone Approved, Vet_approved Phase 1, Phase 2 50-23-7 5754
31
Hydrocortisone acetate Approved, Vet_approved Phase 1, Phase 2 50-03-3
32
Simvastatin Approved Phase 2 79902-63-9 54454
33
Etanercept Approved, Investigational Phase 2 185243-69-0
34
Afamelanotide Approved, Investigational Phase 2 75921-69-6
35
Atorvastatin Approved Phase 2 134523-00-5 60823
36
Apremilast Approved, Investigational Phase 2 608141-41-9 11561674
37
Pembrolizumab Approved Phase 2 1374853-91-4
38
leucovorin Approved Phase 2 58-05-9 6006 143
39
Methotrexate Approved Phase 2 59-05-2, 1959-05-2 126941
40
Tofacitinib Approved, Investigational Phase 2 477600-75-2
41
Durvalumab Approved, Investigational Phase 2 1428935-60-7
42
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
43
Bavituximab Investigational Phase 2 648904-28-3
44 Hydrocortisone 17-butyrate 21-propionate Phase 1, Phase 2
45 Hydrocortisone-17-butyrate Phase 1, Phase 2
46 Hydrocortisone hemisuccinate Phase 1, Phase 2
47 Hypolipidemic Agents Phase 2
48 Lipid Regulating Agents Phase 2
49 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 2
50 Anticholesteremic Agents Phase 2
51 Analgesics, Non-Narcotic Phase 2
52 Anti-Inflammatory Agents, Non-Steroidal Phase 2
53 Antimetabolites Phase 2
54 Antirheumatic Agents Phase 2
55 Immunoglobulins Phase 2
56 Antibodies Phase 2
57 Antibodies, Monoclonal Phase 2
58 Janus Kinase Inhibitors Phase 2
59 Vitamin B Complex Phase 2
60 Folic Acid Antagonists Phase 2
61 Folate Phase 2
62 Vitamin B9 Phase 2
63 Protein Kinase Inhibitors Phase 2
64 interferons Phase 2
65 Antineoplastic Agents, Immunological Phase 2
66
Abatacept Approved Phase 1 332348-12-6 10237
67
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 1 1177-87-3
68
Dexamethasone Approved, Investigational, Vet_approved Phase 1 50-02-2 5743
69 Ginkgo Phase 1
70 Gastrointestinal Agents Phase 1
71 Antineoplastic Agents, Hormonal Phase 1
72 Antiemetics Phase 1
73 Vaccines Phase 1
74
Streptomycin Approved, Vet_approved 57-92-1 19649
75
Petrolatum Approved, Investigational 8009-03-8
76
Fluticasone Approved, Experimental Early Phase 1 90566-53-3 62924
77
Parathyroid hormone Approved, Investigational 9002-64-6
78
Acitretin Approved 55079-83-9, 69427-46-9 6437841
79
Betamethasone Approved, Vet_approved 378-44-9 9782
80
Lidocaine Approved, Vet_approved 137-58-6 3676
81
Povidone-iodine Approved 25655-41-8
82
Epinephrine Approved, Vet_approved 51-43-4 5816
83
Racepinephrine Approved 329-65-7 838
84
Lithium carbonate Approved 554-13-2
85
Ethanol Approved 64-17-5 702
86
Dinoprost Approved, Investigational 551-11-1 5283078
87
Dinoprost tromethamine Approved, Vet_approved 38562-01-5 5282415
88
Vitamin D Approved, Nutraceutical, Vet_approved 1406-16-2
89 penicillins
90 Emollients
91 Antiviral Agents
92 Respiratory System Agents Early Phase 1
93 Anti-Asthmatic Agents Early Phase 1
94 Anti-Inflammatory Agents Early Phase 1
95 Anti-Allergic Agents Early Phase 1
96 Protective Agents
97 Sunscreening Agents
98 Radiation-Protective Agents
99 Calcium, Dietary
100 Bronchodilator Agents Early Phase 1
101 Vitamins
102 Calciferol
103 Calcipotriene
104 Keratolytic Agents
105 Analgesics
106 Hemostatics
107 Epinephryl borate
108 Cardiac Glycosides
109 Peoniflorin
110 Antidepressive Agents
111 Psychotropic Drugs
112 Anti-Bacterial Agents
113 Antibiotics, Antitubercular
114 DEFB1 protein, human
115 Defensins
116
Calcium Nutraceutical 7440-70-2 271

Interventional clinical trials:

(showing 157, show less)
# Name Status NCT ID Phase Drugs
1 Bimatoprost 0.03% Solution, NB-UVB and Fractional Carbon Dioxide Laser in Treatment of Generalized Vitiligo Unknown status NCT03487042 Phase 4 Bimatoprost 0.03% ophthalmic solution
2 Vitiligo and the Koebner Phenomenon (Model of Vitiligo Induction and Therapy: a Clinical and Immunological Analysis) Unknown status NCT01082393 Phase 4 topical tacrolimus treatment;topical pimecrolimus treatment;local mometasone furoate treatment;cold cream
3 Comparison the Efficacy and Safety of 0.1% Tacrolimus Ointment With 0.1% Mometasone Furoate Cream in the Treatment of Adult Vitiligo: A Single Blinded Pilot Study Unknown status NCT01333410 Phase 4 tacrolimus ointment;Mometasone furoate
4 Autologous Punch Grafting in Vitiligo Patients: the Effect of Punchdepth and Punchsize Unknown status NCT01377077 Phase 4
5 Autologous Cell Suspension Grafting Using ReCell in Vitiligo and Piebaldism Patients: a Randomized Controlled Pilot Study Unknown status NCT01640678 Phase 4
6 Effect of Fluticasone Proprionate 0.05% Cream on Narrow Band UV-B Phototherapy in Active Vitiligo: a Randomised Single Blinded Controlled Trial Unknown status NCT01246921 Phase 4 Fluticasone proprionate 0.05% cream
7 Prospective Open Parallel Right to Left Bilateral Study Comparing Narrowband Ultraviolet B Alone Versus Narrowband Ultraviolet B and Psoralen Plus Ultraviolet A for the Treatment of Vitiligo Completed NCT01732965 Phase 4
8 Botulinum Toxin Treatment for Localized Vitiligo Completed NCT01051687 Phase 4 Botulinum toxin A
9 Autologous Cell Suspension Grafting Using ReCell in Vitiligo and Piebaldism Patients: a Randomized Controlled Study on the Recipient Site Preparation Completed NCT02458417 Phase 4
10 Effectiveness of Narrow-band Ultraviolet B Combined With Topical Tacrolimus 0.03% in Treatment of Patients With Vitiligo Recruiting NCT03199664 Phase 4
11 Efficacy and Safety of Topical Bimatoprost Solution 0.03% in Stable Vitiligo:A Preliminary Study Withdrawn NCT01202513 Phase 4 Bimatoprost 0.03% topical ophthalmic solution
12 Efficacy of Tacrolimus Ointment 0.1% Versus Placebo in Adults With Facial Non-segmental Vitiligo: a Randomized Double-blind Controlled Study Unknown status NCT02466997 Phase 3 tacrolimus;Placebo
13 Continuative vs Sequential Phototherapy in Non-segmental Vitiligo Patients Unknown status NCT00525395 Phase 3
14 Safety and Efficacy of Melanocyte-keratinocyte Transplantation in the Treatment of Vitiligo Completed NCT00830713 Phase 3
15 Comparative Study of 308nm Excimer Lamp and 308nm Excimer Laser in the Treatment of Vitiligo Completed NCT00696358 Phase 3
16 A Multicenter Double-blind Placebo-controlled Trial of Non-cultured Epidermal Cellular Grafting Versus Hyaluronic Acid for Repigmenting Stable Leukoderma (Vitiligo and Piebaldism) Completed NCT02156427 Phase 3
17 Treatment of Vitiligo With Narrowband UVB (TL01) Combined With Tacrolimus (0.1%) Versus Placebo Ointment, a Randomized Right/Left Double Blind Comparative Study Completed NCT00807690 Phase 3 Tacrolimus ointment
18 Autologous Transplantation of Melanocytes for Treatment of Vitiligo Skin Completed NCT00631865 Phase 3
19 Efficacy and Tolerance of Transplantation of Harvested Epidermal Cells and Narrow-Band UVB in Vitiligo Completed NCT01629979 Phase 2, Phase 3
20 Interest of the Dermabrasion by Laser Erbium in the Treatment of the Vitiligo Completed NCT01087216 Phase 2, Phase 3 Bras B : The group control
21 Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2): A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo Recruiting NCT04057573 Phase 3 Ruxolitinib cream;Vehicle
22 Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TRuE-V1): A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo Recruiting NCT04052425 Phase 3 Ruxolitinib cream;Vehicle
23 Intralesional Candidal Antigen Versus Intralesional Zinc Sulphate in Treatment of Cutaneous Warts, A Randomized Clinical Trial Recruiting NCT03158168 Phase 3 Candida Antigen;Zinc Sulfate
24 Effectiveness of Microneedling and Topical Latanoprost in Treatment of Acrofacial Vitiligo Not yet recruiting NCT03611348 Phase 2, Phase 3 Latanoprost
25 Assessing the Efficacy of Needling With or Without Corticosteroids in the Repigmentation of Vitiligo Terminated NCT02191748 Phase 2, Phase 3 Triamcinolone
26 Maintenance Treatment of Non Segmental Vitiligo With Tacrolimus Ointment 0.1% Versus Control, Randomized and Double Blind Study Terminated NCT01841008 Phase 2, Phase 3 Protopic;Placebo : Diprobase
27 Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Parallel Group Study of the Efficacy and Safety of ACH24 in the Treatment of Vitiligo Withdrawn NCT01419964 Phase 3 Group 01;Group 02
28 Comparative Study of the Use of Trypsin Versus Dispase in Melanocyte-Keratinocyte Transplantation for the Treatment of Vitiligo Withdrawn NCT01822379 Phase 2, Phase 3
29 Treatment and Complication of Bath PUVA in Vitiligo Unknown status NCT00380471 Phase 2
30 Efficacy of Red Light in Vitiligo: A Prospective, Single-Blind Randomized Controlled Trial Unknown status NCT01787708 Phase 2
31 Efficacy and Safety of Intralesional Triamcinolone Acetonide in Vitiligo: A Prospective, Double-Blind Randomized Controlled Trial Unknown status NCT01766609 Phase 2 Triamcinolone Acetonide
32 UVA 1 Phototherapy for Vitiligo Unknown status NCT01787695 Phase 2
33 The Evaluation of Vitiligous Lesions Repigmentation After the Administration of Atorvastatin Calcium Salt and Simvastatin-acid Sodium Salt in Patients With Active Vitiligo (EVRAAS) Unknown status NCT03247400 Phase 1, Phase 2 1% simvastatin-acid sodium salt ointment;1% atorvastatin calcium salt ointment
34 Effectivness of Topical Tacrolimus 0.03% Monotherapy in Patients With Vitiligo: Arandomized Controlled Trial Unknown status NCT03358082 Phase 1, Phase 2 Tacrolimus 0.03% Ointment;Hydrocortisone Acetate 1% Ointment
35 Topical Psoralen Ultraviolet Light A Versus Narrow Band Ultraviolet Light B Treatment for Recalcitrant Dermatoses of the Hand: A Prospective Randomized, Single-blinded Controlled Clinical Trial Unknown status NCT01792245 Phase 2
36 A Phase-II, Randomized, Placebo-controlled Trial of Simvastatin in Generalized Vitiligo Completed NCT01517893 Phase 2 Simvastatin;Placebo
37 Efficacy and Safety of Pimecrolimus for the Treatment of Vitiligo Vulgaris Completed NCT00372307 Phase 2 Application of pimecrolimus
38 Pilot, Investigator-Initiated, Proof-of-Concept, Study of the Efficacy and Safety of Etanercept (Enbrel) in Adults With Vitiligo Completed NCT00134368 Phase 2 Etanercept
39 A Phase II Randomised Pilot Study to Compare the Efficacy and Safety of Subcutaneous, Bioresorbable Afamelanotide Implants and Narrow-Band Ultraviolet B (NB-UVB) Light in the Treatment of Nonsegmental Vitiligo Completed NCT01382589 Phase 2 Afamelanotide
40 Open Label Phase 2 Proof-of-concept Pilot Trial of Topical Ruxolitinib in Repigmenting Adult Patients With Vitiligo Completed NCT02809976 Phase 2 Ruxolitinib 1.5% Phosphate Cream
41 Study of Applications of Autologous Epidermal Cells in Liquid Phase in the Treatment of Vitiligo Completed NCT01511965 Phase 1, Phase 2
42 Phase I-II, Randomized, Intraindividually Placebo Controlled Clinical Trial, to Evaluate the Efficacy of Autologous Melanocyte Transplantion on Amniotic Membrane as a Substrate for Patients With Stable Vitiligo. Completed NCT01701648 Phase 1, Phase 2
43 Atorvastatin in Active Vitiligo: a Bicentric Prospective Randomized Trial Completed NCT02432534 Phase 2 Atorvastatin
44 A Split Body Study of the Effects of Combined Therapy With Narrow-Band Ultraviolet B Phototherapy and Apremilast for the Treatment of Vitiligo Completed NCT03123016 Phase 2 Apremilast
45 Repigmentation Using Apremilast and Phototherapy In Diffuse VITILIGO RAPID VITILIGO Completed NCT03036995 Phase 2 Apremilast
46 A Phase 2a, Randomized, Double-Blind, Vehicle-Controlled Study to Assess the Safety, Tolerability, and Systemic Exposure of Cerdulatinib Gel, 0.37% in Adults With Vitiligo Recruiting NCT04103060 Phase 2 Cerdulatinib 0.37% gel;Vehicle gel
47 A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy Recruiting NCT03076554 Phase 2 Avelumab
48 A Phase II Study of Pembrolizumab and Bavituximab in Patients With Advanced Hepatocellular Carcinoma Recruiting NCT03519997 Phase 2 Pembrolizumab;Bavituximab
49 A Randomized, Double-Blind, Dose-Ranging Study of INCB018424 Phosphate Cream in Subjects With Vitiligo Active, not recruiting NCT03099304 Phase 2 Ruxolitinib cream;Vehicle cream
50 An Open-Label Pilot Study of the Safety, Tolerability and Efficacy of ATI-50002 Topical Solution Administered Twice-Daily in Adult Subjects With Non-Segmental Facial Vitiligo Active, not recruiting NCT03468855 Phase 2 ATI-50002 topical solution
51 A PHASE 2B RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06651600 WITH A PARTIALLY BLINDED EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF PF-06651600 AND PF-06700841 IN SUBJECTS WITH ACTIVE NON-SEGMENTAL VITILIGO Active, not recruiting NCT03715829 Phase 2 PF-06651600;PF-06651600;PF-06651600;PF-06651600;PF-06651600;placebo;PF06700841
52 Evaluation of AMG 714 for Vitiligo: A Phase 2a Randomized Double Blind Placebo Controlled Trial (ITN086AI) Not yet recruiting NCT04338581 Phase 2
53 Efficacy and Tolerance of the Combination of Methotrexate and Phototherapy Versus Phototherapy in Adults With Progressive Vitiligo: a Randomized Double-blind Prospective Study Not yet recruiting NCT04237103 Phase 2 Methotrexate;Placebos
54 Safety and Efficacy of Tofacitinib for Immune Skin Conditions in Down Syndrome Not yet recruiting NCT04246372 Phase 2 Tofacitinib
55 Durvalumab (MEDI4736) as Maintenance Treatment Following Chemoradiation for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (DESC). Not yet recruiting NCT04054518 Phase 2 Durvalumab
56 A Phase II, Open-Label Trial of Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic Carcinoma Not yet recruiting NCT04417660 Phase 2 M7824
57 Double Blind Within-Subject Controlled Study of Autologous Hair Follicle Outer-Root-Sheath Melanocytes Transplantation in the Treatment of Vitiligo Terminated NCT01923142 Phase 2
58 A Randomized Controlled Pilot Study to Examine the Use of Micrografting, Using a Novel Grafting Technique for the Repigmentation of Vitiligo Terminated NCT01262547 Phase 2
59 The Effect of Preceding Fractional Co2 Laser Either With Tacrolimus, Calcipotriol or With NB-UVB in the Treatment of Stable Generalized Vitiligo Unknown status NCT03234673 Phase 1 Tacrolimus ointment;calcipotriol ointment;NB-UVB
60 Open-label Pilot Study of Abatacept for the Treatment of Vitiligo Unknown status NCT02281058 Phase 1 Abatacept
61 Molecular Mechanisms of Helium-Neon Laser on Melanocyte Regeneration in Skin Equivalent Vitiligo Model Unknown status NCT00172939 Phase 1
62 Effects of Combination Therapy Between Camouflage and Topical Application and/or NB-UVB in the Repigmentation of Vitiligo: an Open-label Self-controlled Study Completed NCT03973073 Phase 1
63 Effect of Procedural-Related Variables on Melanocyte-Keratinocyte Suspension Transplantation in Non-Segmental Stable Vitiligo: A Clinical and Immunohistochemical Study Completed NCT02510651 Phase 1
64 Proof of Concept Study to Compare Efficacy and Safety of Subcutaneous, Bioresorbable Afamelanotide Implants and Narrow-Band Ultraviolet B (NB-UVB) Light Versus NB-UVB Light Alone in the Treatment of Nonsegmental Vitiligo Completed NCT01430195 Phase 1 Afamelanotide
65 Ginkgo Biloba for the Treatment of Vitiligo Vulgaris in Adolescents: an Open Label Pilot Clinical Trial Completed NCT00907062 Phase 1
66 The Reflection of Skin Color on the Efficacy of Narrow Band UVB in Stabilization of Active Cases of Vitiligo Recruiting NCT04030988 Phase 1 Oral dexamethasone minipulse;Placebo oral tablet
67 Treatment of Patients With Castration Resistant Prostate Cancer Using a Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines Active, not recruiting NCT03481816 Phase 1
68 Audiological Disturbances in Vitiligo Unknown status NCT00484224
69 Expression of LC3-I, LC3-II & Beclin 1 in Vitiligo and Healthy Control; Comparative Study Unknown status NCT03371758
70 Maintenance Therapy of 308-nm Excimer Laser Therapy in Patients With Vitiligo Unknown status NCT03384459
71 The Mechanism of Melanocyte Self-Assembly on Biomaterials and the Functional Analysis Unknown status NCT00509314
72 Maintenance Therapy of Narrow-band UV-B Therapy in Patients With Vitiligo Unknown status NCT03384342
73 Development and Psychometric Validation of the Chinese Version of Vitiligo Life Quality Index and Effects of Camouflage on the Life Quality of Patients With Vitiligo: A Randomized Open-label Controlled Study Unknown status NCT03540966 Early Phase 1
74 Efficacy of 311-nm Ti:Sapphire Laser Versus 308-nm Excimer Laser Treatment in Vitiligo Unknown status NCT02925767
75 Transplantation With Dermarolling System of Basal Cell Layer Suspension Obtained by Soft Trypsinisation in Vitiligo Lesion Unknown status NCT02962180
76 Expression of Erythroid Differentiation Regulator 1 (Erdr1) Cytokine in the Vitiliginous Skin Lesions: a Case Control Study Unknown status NCT03377998
77 Oral Ginkgo Biloba and Narrow Band UVB in the Treatment of Vitiligo : A Randomized Double - Blind Placebo Controlled Trial Unknown status NCT01006421
78 Efficacy of Intralesional Triamcinolone Injection in the Treatment of Vitiligo Unknown status NCT03365141 Triamcinolone acetonide 0.4mg/cc;Topical tacrolimus
79 Comparative Study of Surgical Treatment of Vitiligo: Microneedling Versus Microneedling With Suspension of Uncultured Epidermal Cells Unknown status NCT03497208
80 Repigmentation Patterns Induced by NB-UVB and Their Relationship With Melanocytic Dynamics in Vitiligo Unknown status NCT02625012
81 Cutaneous JAK Expression in Vitiligo and Acne Vulgaris. Unknown status NCT03185312
82 A Comparative Study Between Autologous Non Cultured Epidermal Cell Suspension Versus Combination of Autologous Non Cultured Epidermal Cell Suspension and Non Cultured Dermal Cell Suspension in Stable Vitiligo Unknown status NCT03013049
83 Prospective Open Label Parallel Study Comparing Use of Carbon Dioxide Laser Versus Dermabrasion for Denuding Epithelium and Collagen Dressing Versus Vaseline Impregnated Gauze for the Melanocyte Keratinocyte Transplant Procedure Unknown status NCT02038257
84 Comparison of the Efficacy of Micro-holes vs. Laser-assisted Dermabrasion, for Repigmenting in Vitiligo Skin Unknown status NCT02660320
85 The Role of Dermoscopy in Diagnosis of Pigmentary Skin Lesions Unknown status NCT03542539
86 Pattern of Skin Manifestations in Chronic Hepatitis c Virus Patients Before and After Direct Acting Anti Viral Drugs: Prospective Controlled Clinical Trial Unknown status NCT03170076
87 A Prospective, Randomized, Controlled Clinical Trial Comparing the Efficacy Carbon Dioxide (CO2) Laser Excision Versus Surgical Deroofing in the Treatment of Hidradenitis Suppurativa Unknown status NCT02163746
88 The Role of Long Wavelength UVA1 Phototherapy in Acral Vitiligo Completed NCT03378011
89 In-depth Analysis of the Implementation of Vitiligo Extent Score (VES) Score in Comparison to Vitiligo Area and Severity Index (VASI) Score Completed NCT03411135
90 Study of the Cutaneous Expression of Thymic Stromal Lymphopoietin (TSLP) in a Sample of Vitiligo Patients Completed NCT03367273
91 Online Health Survey of Patients With Vitiligo Vulgaris/ Online Survey of Pediatric Patients With Vitiligo Completed NCT01401374
92 Leucotrichia in Vitiligo Patients : A Cross Sectional Study Completed NCT03402633
93 Optimal Treatment Frequency of 308-Nm Excimer Laser for Vitiligo on the Face and Neck Completed NCT00368407
94 Demographic and Laboratory Data Collection for Patients With Vitiligo Vulgaris Completed NCT01206374
95 Determining the Tolerance of Depigmented Skin to Targeted Phototherapy Using UVB in Patients With Vitiligo Completed NCT00367224
96 To Study the Efficacy of Therapeutic Pulsed Ultrasound in the Treatment of Vitiligo: a Randomized, Intra-individual, Left-right Comparison Study Completed NCT03864315
97 Expression of Janus Kinase 1 in Vitiligo and Psoriasis Before and After Narrow Band UVB: a Case-Control Study Completed NCT03762551
98 Metabolic Syndrome in Early Onset Versus Late Onset Vitiligo Completed NCT03622320
99 The Effect of UVB Phototherapy With Microneedling and Circled Needing in Vitiligo Patients Completed NCT03718962
100 Pilot Study of Novel Topical Drug (Photocil) for the Treatment of Vitiligo Completed NCT01992185 Photocil for Vitiligo
101 The Efficacy of Hand-Foot Narrow-Band Ultraviolet B (UVB) Versus Focal 308-nm Treatment in Inducing Repigmentation of Vitiligo After Minigrafting on the Dorsal Hands Completed NCT00622180
102 Study of the Role of Innate Lymphoid Cells and Natural Killer Cells in Immune Activation of Vitiligo Completed NCT03859518
103 Response to Tregs in Innate Immunity Receptor LRP1 (CD91) and Tregs in Periferic Blood Mononuclear Cells in Patients With Non-segmentary Vitiligo Completed NCT03249064
104 Photoprotection Habits in Patients With Vitiligo Completed NCT03323125
105 Effects of Narrowband UVB Phototherapy on Melanocyte Proliferation in Patients With Vitiligo Completed NCT00398723
106 Comparison of Scanoskin With Planimetry as an Objective Measure of Vitiligo. Completed NCT03133871
107 Quality of Life, Emotional and Sleep Problems in Chronic Skin Diseases Completed NCT00167752
108 Efficacy of Narrow-band UVB Treatment After Transplantation of Harvested Epidermal Cells in Vitiligo Completed NCT00615355
109 The Efficiency of Fractional-Laser Resurfacing Followed by Topical Tacrolimus 0.03% Cream Versus Topical Tacrolimus Alone in Stable Vitiligo: a Comparative Study Completed NCT03535051 Tacrolimus Oint 0.03%
110 Comparison of Cyclic On-off and Continuous Excimer Laser Treatment for Vitiligo: A Randomized Controlled Non-inferiority Trial Completed NCT03047733 Topical tacrolimus 0.1% ointment
111 Pilot Randomised Controlled Trial of Hand Held NB-UVB for the Treatment of Focal or Early Vitiligo at Home Completed NCT01478945
112 A Randomized Double-Blind Placebo Controlled Study Evaluating the Effectiveness and Tolerability of Oral Polypodium Leucotomos in Patients With Melasma Completed NCT01162850
113 A Pilot Study of Vitamin D in Subjects With Alopecia Areata Completed NCT01328678
114 Excimer Light Treatment for Idiopathic Guttate Hypomelanosis: A Pilot Study Completed NCT01956435
115 Potential Research Study Participant Registry Completed NCT00710489
116 Impact of Long Wavelength UVA and Visible Light on Melanocompetent Skin Completed NCT00478751
117 Microneedling for Acquired Hypomelanosis : A Randomized Controlled Trial Completed NCT04419350
118 Assessment of the Role of the JAK-STAT Pathway in the Pathogenesis of Male Androgenetic Alopecia Completed NCT03694067
119 The Use of Topical Nasal Steroids for Skin Reactions to Continuous Glucose Monitoring System, Among Children and Youth With Type 1 Diabetes Mellitus: Case Series Completed NCT03594565 Early Phase 1 Fluticasone Propionate
120 Assessment of the Combined Effect of Acitretin and Narrow Band Ultraviolet B on the Clinical Repigmentation and on the Expression of E-cadherins in Vitiligo Lesions in Comparison to Narrow Band UVB Alone. A Pilot Study Recruiting NCT04245319 Acitretin
121 Comparison of the Efficacy of Tacrolimus 0.1% Ointment vs Calcipotriol/Betamethasone in Combination With NBUVB in Treatment of Vitiligo Recruiting NCT04440371
122 The Gut and Skin Microbiome in Vitiligo Disease Progression Recruiting NCT03577327
123 Stress Response Pathways in Vitiligo: A Prospective, Investigator Initiated, Interventional Study With Two Arms Recruiting NCT02797574
124 The Gut Microbiome and Metabolic Activity in Patients With Vitiligo Recruiting NCT03797417
125 Gastroprotected Superoxide Dismutase in Combination With UVB vs Placebo and UVB for Treating Vitiligo. A Randomized Double Blind Placebo Controlled Monocentric Study Recruiting NCT03941808 Glisodin tablet;Placebo tablet
126 Early Molecular Changes in Vitiligo After Narrowband Ultraviolet Therapy Recruiting NCT03270241
127 The Investigation on the Expression of High Mobility Group Protein Box-1 (HMGB1) in Peripheral Blood of Vitiligo Patients and Healthy Controls According to Clinical Features, Treatment and Disease Activity Recruiting NCT03741738
128 Punch Minigraft Versus Transverse Needling or Combination of Both in Treatment of Non-Segmental Vitiligo Recruiting NCT03872804
129 A Prospective, Double-blind, Split-body, Randomized Controlled Trial to Assess the Efficacy of Low Level Laser Therapy for Pigmentary Disorders Recruiting NCT04308421
130 PHNA, Efficacy of Tretinoin Cream on Post-phototherapy Hyperpigmentation Recruiting NCT03933774 Tretinoin 0.05% cream;Placebo cream
131 Evaluating the Efficacy of the Melanocyte Keratinocyte Transplantation Procedure in the Treatment of Vitiligo Recruiting NCT04374435
132 A Comparative Study Between Recipient Site Preparation Using Dermabrasion,Liquid Nitrogen Induced Blister and Dermarolling System in Autologous Non Cultured Epidermal Cell Suspension Procedure in Stable Vitiligo Patients. Recruiting NCT03668834
133 Determining the Association Between Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity Recruiting NCT03941184
134 A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Immune-Mediated Inflammatory Skin Conditions Recruiting NCT03661866
135 A Comparative Study Between Autologous Mini Punch Grafting, Suction Blister Grafting and Non-Cutured Epidermal Cell Suspension on Resistant Sites in Stable Vitiligo Recruiting NCT03717025
136 Explorative Investigations on the Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases Recruiting NCT03340155
137 A Pragmatic Trial of Home Versus Office Based Narrow Band Ultraviolet B Phototherapy for the Treatment of Psoriasis Recruiting NCT03726489
138 A Single Center, Double-blinded Randomized Placebo-controlled Trial to Evaluate Surgical Scars After Treatment With Fractional Carbon Dioxide Rejuvenation Laser Therapy Active, not recruiting NCT02985151
139 Efficacy and Safety of Total Glucosides of Paeony Combined With NB-UVB in the Treatment of Sporadic Vitiligo in Proceeding: a Double-blind, Randomized, Placebo-controlled Trial Enrolling by invitation NCT03608917 Total Glucosides of Paeony(TGP);Total Glucosides of Paeony(TGP) analogue
140 Evaluation of the Efficacy and the Cutaneous Acceptability of a Dermocosmetic Product in the Repigmentation of Vitiligo -Study Realized by a Dermatologist- Enrolling by invitation NCT04171427
141 Long-term Ten Years Follow-up in Patients Affected With Acrofacial Vitiligo Not yet recruiting NCT01459055
142 Prevalence of Psoriasis and Vitiligo in Assiut Governorate, Egypt Not yet recruiting NCT04039451
143 Treatment of Acral Vitiligo : Narrowband Ultraviolet-B and Microneedling With and Without Platelet Rich Plasma Not yet recruiting NCT03155698
144 Estimation of Tissue Level of Human Beta-defensin 1 (HBD-1) in Vitiligo Before and After Narrowband UVB Phototherapy: a Case-control Study Not yet recruiting NCT03832751
145 Study of the Cutaneous Expression of Prostaglandin F2-alpha (PGF2α) in Vitiligo Patients: a Case-control Study. Not yet recruiting NCT03755830
146 Analysis of Inflammation in the Vitiligo and Other Inflammatory Skin Diseases: Psoriasis, Atopic Dermatitis and Alopecia Areata Not yet recruiting NCT03976622
147 Fractional Carbon Dioxide Laser Combined With Topical Corticosteroid and Narrow Band Ultraviolet B in Treatment of Stable Vitiligo. Not yet recruiting NCT03158675 Topical corticosteroid
148 A Prospective Blinded Randomized Within-Subject Controlled Clinical Feasibility Study to Evaluate RECELL and Melanocyte Keratinocyte Transplantation Procedure (MKTP) for Repigmentation of Stable Vitiligo Lesions Not yet recruiting NCT04271501
149 Structural Evaluation of Human Melanocytes After the Use of Autologous Platelet-rich Plasma (PRP) Versus Fractional Carbon Dioxide Laser (Fr:CO2 Laser) in Treatment of Vitiligo: (A Histological, Immunohistochemical and Molecular Study ) Not yet recruiting NCT04320160
150 Hypo-pigmented Skin Lesions in Children : Dermoscopic Evaluation Not yet recruiting NCT04089475
151 The Epidemiology, Management, and the Associated Burden of Mental Health, Atopic and Autoimmune Conditions in Alopecia Areata Not yet recruiting NCT04239521
152 Treatment of Recalcitrant Forms of Vitiligo With a Low-energy 635 nm Visible Light Laser Terminated NCT01259986
153 Characterization of Keratinocyte Populations From Normal, Perilesional and Lesional Skin in Vitiligo Patients by Laser Capture Microdissection and Gene Array Analysis Before and After Narrow Band UVB Treatment Terminated NCT00177034 Narrow Band UVB Treatment
154 In Vivo Imaging of Pigmentary Disorders by Reflectance Confocal Microscopy Terminated NCT00771355
155 Randomized, Split-Body, Single-Blinded Clinical Trial of Narrow Band-Ultraviolet B (NB-UVB) Treatment for Vitiligo Terminated NCT02506101
156 Autologous Cell Suspension Grafting Using ReNovaCell in Non-segmental Vitiligo Patients: a Randomized Controlled Study Terminated NCT03022019
157 Fractional Laser Abrasion in Combination With UVB Therapy in Vitiligo Patients: a Randomized Controlled Study. Withdrawn NCT02290717 Fluticasone Propionate Cream 0.05%

Search NIH Clinical Center for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Methoxsalen
monobenzone
Trioxsalen

Genetic Tests for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Anatomical Context for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

MalaCards organs/tissues related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6:

40
Skin, T Cells, Thyroid, Testes, Liver, Eye, Bone

Publications for Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6

Articles related to Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 6:

(showing 6859, show less)
# Title Authors PMID Year
1
Genome-wide association study for vitiligo identifies susceptibility loci at 6q27 and the MHC. 56 61
20526339 2010
2
Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo. 56 61
20410501 2010
3
Vitiligo: complex segregation and linkage disequilibrium analyses with respect to microsatellite loci spanning the HLA. 56 61
11941482 2002
4
The influence of interferon on healthy and diseased skin. 61
30527631 2020
5
A prospective study to assess the efficacy of various surgical modalities in treatment of stable vitiligo patches over resistant sites. 61
32386068 2020
6
Altered expression of nuclear factor of activated T cells, forkhead box P3, and immune-suppressive genes in regulatory T cells of generalized vitiligo patients. 61
31917889 2020
7
Increased risk of endocrine autoimmunity in first-degree relatives of patients with autoimmune Addison's disease. 61
32487775 2020
8
Assessment of suicidal behavior in dermatology (Review). 61
32508997 2020
9
Skin - a vast organ with immunological function (Review). 61
32508987 2020
10
Extensive vitiligo associated to response to c-kit inhibitor in metastatic mucosal melanoma. 61
32011367 2020
11
Diterpenes with potential treatment of vitiligo from the aerials parts of Euphorbia antiquorum L. 61
32234374 2020
12
Proceeding Report of the Second Vitiligo International Symposium-November 9-10, 2018, Detroit, Michigan, USA. 61
31984599 2020
13
Factors affecting the outcome of the suction blisters using two different harvesting techniques in vitiligo patients. 61
31746546 2020
14
Nonsegmental vitiligo follows Blaschko's lines and embryonic pigmentary segments. 61
31898641 2020
15
Genital vitiligo with reticular pigmentation in a male patient. 61
31793664 2020
16
A novel point of care technique to improve graft uptake in melanocyte-keratinocyte transplantation procedure for vitiligo of contoured areas like external ear. 61
32497701 2020
17
Vitiligo expansion and extent correlate with durable response in anti-programmed death 1 antibody treatment for advanced melanoma: A multi-institutional retrospective study. 61
32275100 2020
18
Intracellular virus sensor MDA5 exacerbates vitiligo by inducing the secretion of chemokines in keratinocytes under virus invasion. 61
32532953 2020
19
Comparative study between follicular unit transplantation with intact and unintact hair bulb in treatment for stable vitiligo. 61
32530337 2020
20
Type-1 cytokines regulate MMP-9 production and E-cadherin disruption to promote melanocyte loss in vitiligo. 61
32369451 2020
21
Near-infrared spectroscopy as a potential non-invasive tool in the assessment of disease activity in vitiligo patients. 61
32267028 2020
22
Aberrant ETS-1 signalling impedes the expression of cell adhesion molecules and matrix metalloproteinases in non-segmental vitiligo. 61
32350934 2020
23
Evaluation of the additional effect of topical 5-fluorouracil to needling in the treatment of localized vitiligo. 61
31524967 2020
24
Evidence of a possible therapeutic role of vitamin D in a cohort of adult Caucasian vitiligo patients. 61
31414974 2020
25
The efficacy of fractional carbon dioxide laser combined with narrow-band ultraviolet B phototherapy for non-segmental vitiligo: a systematic review and meta-analysis. 61
32572662 2020
26
The Effect of Isotretinoin on Vitiligo and Autoimmune Comorbidity. 61
32574013 2020
27
NKG2D Defines a Subset of Skin Effector Memory CD8 T Cells with Proinflammatory Functions in Vitiligo. 61
31877315 2020
28
Association study between vitiligo and autoimmune-related genes CYP27B1, REL, TNFAIP3, IL2 and IL21. 61
32282963 2020
29
Polygenic risk for skin autoimmunity impacts immune checkpoint blockade in bladder cancer. 61
32430334 2020
30
Association between immune-related adverse events and efficacy of PD-1 inhibitors in Chinese patients with advanced melanoma. 61
32516130 2020
31
Off-label studies on ruxolitinib in dermatology: a review. 61
32515635 2020
32
It's Not All Sunshine: Non-sun-related Melanoma Risk-factors. 61
32346749 2020
33
Correlation between cutaneous adverse events and prognosis in patients with melanoma treated with nivolumab: A single institutional retrospective study. 61
32162349 2020
34
It Takes Two to Tango. 61
32446332 2020
35
Genome-wide association study identifies CDH13 as a susceptibility gene for rhododendrol-induced leukoderma. 61
32558222 2020
36
Retinal nerve fiber layer, retinal pigment epithelium, and choroidal thickness in vitiligo patients. 61
32515874 2020
37
Afamelanotide implants and narrow-band ultraviolet B phototherapy for the treatment of nonsegmental vitiligo in Asians. 61
31987791 2020
38
Micropunch grafting as an adjuvant for noncultured melanocyte-keratinocyte transplantation for refractory vitiligo. 61
32160974 2020
39
Vitiligo-like depigmentation after chromoblastomycosis: a kind of postinflammatory depigmentation due to fungal infection. 61
32556927 2020
40
Evaluating Population Interest in Vitiligo Through an Analysis of Google Trends and Social Media. 61
32574016 2020
41
Expression of immune checkpoints in active nonsegmental vitiligo: a pilot study. 61
32557594 2020
42
Microdermabrasion and topical tacrolimus: A novel combination therapy of vitiligo. 61
31668003 2020
43
Chemical-Associated Vitiligo. 61
32498770 2020
44
Repigmentation of vitiligo with oral baricitinib. 61
32491188 2020
45
CHARACTERISTICS OF GRAVES DISEASE IN HIV-INFECTED PATIENTS ON ANTIRETROVIRAL THERAPY. 61
31968184 2020
46
Comorbidities in Pediatric Alopecia Areata. 61
32531131 2020
47
Vernonia anthelmintica (L.) Willd.: An ethnomedicinal, phytochemical, pharmacological and toxicological review. 61
32205258 2020
48
Integrative proteomics-metabolomics strategy reveals the mechanism of hepatotoxicity induced by Fructus Psoraleae. 61
32240813 2020
49
Associations of Angiotensin-Converting Enzyme Gene Insertion/Deletion (ACE Gene I/D) Polymorphism With Vitiligo: An Updated Systematic Review and Meta-Analysis. 61
32528781 2020
50
Can we consider silymarin as a treatment option for vitiligo? A double-blind controlled randomized clinical trial of phototherapy plus oral Silybum marianum product versus phototherapy alone. 61
30935260 2020
51
Skin seeding technique with 0.5-mm micropunch grafting for vitiligo irrespective of the epidermal-dermal orientation: Animal and clinical studies. 61
32452060 2020
52
Effective use of oral tofacitinib and phototherapy in a patient with concomitant alopecia areata, vitiligo, and plaque and inverse psoriasis. 61
32477525 2020
53
Electrocautery Needling and the 308-nm Excimer Lamp: A Synergistic Combination for the Treatment of Stable Non-segmental Vitiligo. 61
32441031 2020
54
Micropigmentation for vitiligo on light to moderately colored skin: Updated evidence from a clinical and animal study. 61
32124487 2020
55
The Role of TRM Cells in the Pathogenesis of Vitiligo-A Review of the Current State-Of-The-Art. 61
32443482 2020
56
Efficacy of noncultured melanocyte-keratinocyte cell suspension vs hair follicular cell suspension transfer in stable vitiligo: A randomized controlled trial. 61
32162392 2020
57
Effectiveness of a combined 308-nm excimer lamp and topical mid-potent steroid treatment for facial vitiligo: a preliminary, randomized double-blinded controlled study. 61
32458080 2020
58
Combination of oral methotrexate and oral mini-pulse dexamethasone vs either agent alone in vitiligo treatment with follow up by dermoscope. 61
32410362 2020
59
Narrow-band ultraviolet B comb as an effective home-based phototherapy device for limited or localized non-segmental vitiligo: A pilot, open-label, single-arm clinical study. 61
32068191 2020
60
Validation of a Patient Global Assessment for extent, severity, and impact to define the severity strata for the Self Assessment Vitiligo Extent Score (SA-VES). 61
32452565 2020
61
Cancer risks in patients with vitiligo: a Mendelian randomization study. 61
32462299 2020
62
Immunomodulatory effects of medicinal plants used for vitiligo in traditional Persian medicine.. 61
32416680 2020
63
Co-aggregation and heritability of organ-specific autoimmunity: a population-based twin study. 61
32229696 2020
64
Scleredema of Buschke associated with lichen sclerosus: Three cases. 61
30289118 2020
65
Off-Label Therapeutic Potential of Crisaborole. 61
32133868 2020
66
Increased risk of psychiatric disorders in adult patients with vitiligo: A nationwide, population-based cohort study in Taiwan. 61
32124495 2020
67
Acquired hemophilia A and other autoimmune diseases after alemtuzumab therapy for multiple sclerosis: A report of two cases. 61
32531751 2020
68
Selenium levels and skin diseases: systematic review and meta-analysis. 61
32497930 2020
69
Inflammatory segmental vitiligo during oral isotretinoin use: a casual association? 61
32299740 2020
70
Gastrointestinal involvement of primary skin diseases. 61
32455473 2020
71
42 °C heat stress pretreatment protects human melanocytes against 308-nm laser-induced DNA damage in vitro. 61
32472428 2020
72
PM2.5 induces apoptosis, oxidative stress injury and melanin metabolic disorder in human melanocytes. 61
32269607 2020
73
RIPK1 regulates the survival of human melanocytes upon endoplasmic reticulum stress. 61
32266019 2020
74
Concurrent Vogt-Koyanagi-Harada disease and impressive response to immune checkpoint blockade in metastatic melanoma. 61
32308086 2020
75
[Vogt-Koyanagi-Harada-like uveitis under immune checkpoint inhibitor treatment for metastasized malignant melanoma]. 61
31489479 2020
76
6-Shogaol Protects Human Melanocytes against Oxidative Stress through Activation of the Nrf2-Antioxidant Response Element Signaling Pathway. 61
32429495 2020
77
CME Part II: Immune checkpoint inhibitor-related dermatologic adverse events. 61
32454097 2020
78
New onset vitiligo in a patient with hidradenitis suppurativa treated with adalimumab. 61
32239739 2020
79
Studying the effect of adding growth factors to the autologous melanocyte keratinocyte suspension in segmental vitiligo. 61
32243651 2020
80
Excimer light therapy in childhood segmental vitiligo: Early treatment gives better results. 61
32304121 2020
81
Deciphering skin re-pigmentation patterns in vitiligo: an update on the cellular and molecular events involved. 61
32433056 2020
82
Interleukin-17 level in patients with vitiligo: A systematic review and meta-analysis. 61
31895472 2020
83
Cosmetic camouflage as an adjuvant to vitiligo therapies: Effect on quality of life. 61
32406129 2020
84
Homocysteine induces melanocytes apoptosis via PERK-eIF2α-CHOP pathway in vitiligo. 61
32400851 2020
85
Commentary on "Razor Blade, A Simple Instrument Used in Epidermic Grafting for Vitiligo". 61
32439461 2020
86
Lesional skin in vitiligo exhibits delayed in vivo reepithelialization compared to the nonlesional skin. 61
32003499 2020
87
Investigation of hearing and outer hair cell function of the cochlea in patients with vitiligo. 61
32475000 2020
88
Does oxidative stress correlate with disease activity and severity in vitiligo? An analytical study. 61
32422682 2020
89
Easy way of making blister in suction blister grafting of vitiligo with 'Hijama' therapy cups. 61
32454099 2020
90
Is targeting circulating T blood cells a therapeutic option for vitiligo? 61
32458433 2020
91
JAK inhibitors reverse vitiligo in mice but do not deplete skin resident memory T cells. 61
32464150 2020
92
Immune checkpoint inhibitor-induced vitiligo in advanced melanoma could be related to increased levels of CCL19. 61
31746456 2020
93
Micropigmentation-A revived therapeutic tool for recalcitrant, difficult-to-treat periungual vitiligo. 61
32401406 2020
94
Partial repigmentation of vitiligo with tofacitinib, without exposure to ultraviolet radiation. 61
32418716 2020
95
Repigmentation of acrofacial vitiligo with subcutaneous tildrakizumab. 61
32441048 2020
96
Psychodermatology of vitiligo: Psychological impact and consequences. 61
32297399 2020
97
Is NAT2 Gene Polymorphism Associated with Vitiligo? 61
32565555 2020
98
Vitiligo and Melanoma-Associated Vitiligo: Understanding Their Similarities and Differences. 61
32468356 2020
99
[Cutaneous Toxicity of Immune Checkpoint Inhibitors: A Narrative Review]. 61
32416756 2020
100
Association between major depressive disorder and subsequent autoimmune skin diseases: A nationwide population-based cohort study. 61
32469824 2020
101
Clinicopathological evaluation of the donor area following autologous suction blister epithelial grafting vs Thiersch grafting in vitiligo patients: A preliminary study. 61
32232886 2020
102
Clinical evaluation of the efficacy of trichloroacetic acid 70% after microneedling vs intradermal injection of 5-fluorouracil in the treatment of nonsegmental vitiligo; A prospective comparative study. 61
32379374 2020
103
A cross-sectional study of spontaneous repigmentation in vitiligo. 61
31793491 2020
104
Reliability and validity of the Vitiligo Signs of Activity Score. 61
32458411 2020
105
Digital ultraviolet B phototherapy in vitiligo: proof of concept. 61
31705524 2020
106
Autoinflammation in addition to combined immunodeficiency: SLC29A3 gene defect. 61
32151906 2020
107
Follicular Transplantation, Microneedling, and Adjuvant Narrow-band Ultraviolet-B Irradiation as Cost-Effective Regimens for Palmar-Plantar Vitiligo: A Pilot Study. 61
32489732 2020
108
The incidence and survival of melanoma and nonmelanoma skin cancer in patients with vitiligo: a nationwide population-based matched cohort study in Korea. 61
31233609 2020
109
Tacrolimus (FK506) ointment combined with Nb-UVB could activate both hair follicle (HF) and dermal melanocyte precursors in vitiligo: the first histopathological and clinical study. 61
32303824 2020
110
Partner bereavement and risk of chronic urticaria, alopecia areata and vitiligo: cohort studies in the UK and Denmark. 61
32282926 2020
111
Lack of association of IL-10 (rs1800896) and IL-13 (rs1800925) with non-segmental vitiligo susceptibility in South Indian population. 61
32295963 2020
112
Evaluation of combined excimer laser and platelet-rich plasma for the treatment of nonsegmental vitiligo: A prospective comparative study. 61
31541597 2020
113
IL-17 and its role in inflammatory, autoimmune, and oncological skin diseases: state of art. 61
31663126 2020
114
[Medicaments and oral healthcare. Hyperpigmentation of oral soft tissues due to afamelanotide]. 61
32459219 2020
115
Vitiligo: Mechanisms of Pathogenesis and Treatment. 61
32017656 2020
116
The necessity of antinuclear antibody investigation in pre-phototherapy vitiligo patients: A retrospective study. 61
32274836 2020
117
Parental risk factors for fever in their children 7-10 days after the first dose of measles-containing vaccines. 61
31584845 2020
118
Viral Kerato-Uveitis with Choroidal Vitiligo. 61
32255709 2020
119
Emerging role of dermal compartment in skin pigmentation: comprehensive review. 61
32243635 2020
120
Nivolumab-induced lichen planus. 61
31382865 2020
121
Role of the p53‑TRPM1/miR‑211‑MMP9 axis in UVB‑induced human melanocyte migration and its potential in repigmentation. 61
31985026 2020
122
Biological Activity of Endophytic Fungi from the Roots of the Medicinal Plant Vernonia anthelmintica. 61
32316675 2020
123
Gender differences in psoriasis: a Swiss online psoriasis survey. 61
32281022 2020
124
Cistanche deserticola polysaccharide induces melanogenesis in melanocytes and reduces oxidative stress via activating NRF2/HO-1 pathway. 61
32096914 2020
125
Single Radiotherapy Fraction with Local Anti-CD40 Therapy Generates Effective Abscopal Responses in Mouse Models of Cervical Cancer. 61
32331490 2020
126
Repigmentation in vitiligo using janus kinase (JAK) inhibitors with phototherapy: systematic review and Meta-analysis. 61
32096671 2020
127
Localized vitiligo occurring in an old biopsy scar: A case report. 61
32258311 2020
128
Efficacy of microneedling combined with tacrolimus versus either one alone for vitiligo treatment. 61
32030880 2020
129
Open-label pilot study of tofacitinib 2% for the treatment of refractory vitiligo. 61
31605536 2020
130
Tofacitinib cream plus narrowband ultraviolet B phototherapy for segmental vitiligo in a child. 61
32255214 2020
131
Audiological Abnormalities in Vitiligo Patients: A Hospital-Based Cross-Sectional Study. 61
32256834 2020
132
Lymphomatoid contact dermatitis caused by textile dye arising on pre-existing vitiligo lesions. 61
32243601 2020
133
Deciphering skin re-pigmentation patterns in vitiligo: an update on the cellular and molecular events involved. 61
32345821 2020
134
Elastin fiber but not collagen fiber is decreased dramatically in the dermis of vitiligo patients. 61
32346870 2020
135
Drug-induced vitiligo: a case/non-case study in Vigibase® , the WHO pharmacovigilance database. 61
32246859 2020
136
Value of silicone gel in prevention of cobblestoning following punch minigrafting in vitiligo. 61
32281443 2020
137
Clinical Reasoning: A 47-year-old man with rapidly progressive ataxia and vitiligo. 61
32165449 2020
138
Razor Blade, A Simple Instrument Used in Epidermic Grafting for Vitiligo. 61
32320769 2020
139
Expression of Th17- and Treg-specific transcription factors in vitiligo patients. 61
31909498 2020
140
Association between vitiligo and smoking: A nationwide population-based study in Korea. 61
32277157 2020
141
Vitiligo and skin cancer: is it a question of ethnicity? 61
31621061 2020
142
Childhood vitiligo in Egypt: Clinico-epidemiologic Profile of 483 patients. 61
32320520 2020
143
Safety of the current drug treatments for vitiligo. 61
32067513 2020
144
Current insight into the roles of microRNA in vitiligo. 61
32086720 2020
145
Advances in fluorescent probes for detection and imaging of endogenous tyrosinase activity. 61
32035843 2020
146
Impact of graft cell density and viability on repigmentation upon noncultured autologous cell suspension transplantation in vitiligo and piebaldism. 61
32311146 2020
147
Vitiligo: to biopsy or not to biopsy? 61
32463851 2020
148
Vitiligo Following Autologous Hematopoietic Stem Cell Transplantation. 61
32057713 2020
149
Childhood vitiligo impacts emotional health of parents: a prospective, cross-sectional study of quality of life for primary caregivers. 61
32193721 2020
150
[Examination of vitiligo using the blue light from the screen of mobile devices as an alternative to a Wood's lamp]. 61
32229031 2020
151
Expression of melanocortin 1 receptor before and after narrowband UVB phototherapy treatment in patients with stable vitiligo: A prospective study. 61
32104216 2020
152
Sensitivity of serum S100B protein as a disease activity marker in Egyptian patients with vitiligo (case-control study). 61
32188291 2020
153
Evaluation for Skin Cancer and Precancer in Patients With Vitiligo Treated With Long-term Narrowband UV-B Phototherapy. 61
32159729 2020
154
Determining the minimal important change scores of the Vitiligo Impact Scale (VIS)-22 and Dermatology Life Quality Index (DLQI) scores in Indian patients with vitiligo using anchor- and distribution-based approaches. 61
32119113 2020
155
A comparative clinical trial to evaluate efficacy and safety of the 308-nm excimer laser and the gain-switched 311-nm titanium:sapphire laser in the treatment of vitiligo. 61
31520445 2020
156
Sub-erythemic and erythemic doses of a 308-nm excimer laser treatment of stable vitiligo in combination with topical tacrolimus: A randomized controlled trial. 61
32171812 2020
157
A randomized pilot study to compare hair follicle cell suspensions prepared using trypsin alone versus trypsin in combination with collagenase type I for transplantation in vitiligo. 61
31361909 2020
158
Vitiligo: A Review. 61
32155629 2020
159
The enigma and challenges of vitiligo pathophysiology and treatment. 61
32198977 2020
160
Comorbid diseases of vitiligo: A 10-year cross-sectional retrospective study of an urban US population. 61
31325552 2020
161
Noncultured epidermal cell suspension for the treatment of recalcitrant segmental vitiligo in a solid-organ transplant recipient. 61
32122692 2020
162
Higher incidence of metabolic syndrome components in vitiligo patients: a prospective cross-sectional study. 61
32113676 2020
163
Associations of pemphigus or pemphigoid with autoimmune disorders in US adult inpatients. 61
31319089 2020
164
Pharmacokinetics, Pharmacodynamics and Dermal Distribution of 5-Methoxypsoralen Based on a Physiologically Based Pharmacokinetic Model to Support Phytotherapy Using Brosimum gaudichaudii. 61
31968379 2020
165
Ablation of DJ-1 Enhances Oxidative Stress by Disturbing the Function of Mitochondria in Epidermal Melanocytes. 61
32180592 2020
166
Psoralen Derivatives with Enhanced Potency. 61
32221980 2020
167
Tissue-resident memory T cells in the skin. 61
31989191 2020
168
Endophytic Bacteria Associated with Medicinal Plant Vernonia anthelmintica: Diversity and Characterization. 61
32211943 2020
169
Apigenin protects human melanocytes against oxidative damage by activation of the Nrf2 pathway. 61
31953635 2020
170
In vitro proliferation of human epidermal melanocytes biopsied from multiple anatomical sites. 61
32125076 2020
171
Molecular Hydrogen Protects Human Melanocytes from Oxidative Stress by Activating Nrf2 Signaling. 61
32234461 2020
172
Long-Term Benefits of Daily Photo-Protection With a Broad-Spectrum Sunscreen in United States Hispanic Female Population. 61
32550692 2020
173
Management of recalcitrant vitiligo in Vogt-Koyanagi-Harada syndrome: Adjuvant ablative fractional laser. 61
32131141 2020
174
Experimental study and clinical observations of autologous hair follicle cell transplants to treat stable vitiligo. 61
31397397 2020
175
Vitiligo under anti-programmed cell death-1 therapy is associated with increased survival in melanoma patients. 61
31734192 2020
176
Association Between Methylenetetrahydrofolate Reductase Gene Polymorphisms and Risk of Vitiligo: A Systematic Review and Meta-Analysis. 61
32162672 2020
177
The impact of NBUVB on microbial community profiling in the lesional skin of vitiligo subjects. 61
31917273 2020
178
GPNMB is expressed in human epidermal keratinocytes but disappears in the vitiligo lesional skin. 61
32188902 2020
179
Needling as a Method to Highlight the Margins of a Vitiligo Patch During Melanocyte-Keratinocyte Transplantation. 61
32205754 2020
180
Therapeutic options in vitiligo with special emphasis on immunomodulators: A comprehensive update with review of literature. 61
31891450 2020
181
Simultaneous Bullous Pemphigoid and Vitiligo Associated with Adalimumab Therapy in a Patient with Psoriasis Vulgaris. 61
32477986 2020
182
Induction of Pigmentation Through Microneedling in Stable Localized Vitiligo Patients. 61
30893180 2020
183
Near total body vitiligo secondary to immunotherapy for metastatic melanoma. 61
32147813 2020
184
Emerging drugs for the treatment of vitiligo. 61
31958256 2020
185
Refractory vitiligo improving with eculizumab. 61
31997487 2020
186
Antibiotics Drive Microbial Imbalance and Vitiligo Development in Mice. 61
31472106 2020
187
Predominant role of innate pro-inflammatory cytokines in vitiligo disease. 61
31620869 2020
188
Sun-protection habits and knowledge of patients with vitiligo. 61
32206816 2020
189
Deep genotype imputation captures virtually all heritability of autoimmune vitiligo. 61
31943001 2020
190
Axillary incubator for cell-based therapies in vitiligo. 61
32222452 2020
191
Author Correction: Micro RNAs upregulated in Vitiligo skin play an important role in its aetiopathogenesis by altering TRP1 expression and keratinocyte-melanocytes cross-talk. 61
32015404 2020
192
Safety and Efficacy of the Combination of 308-nm Monochromatic Excimer Light and Topical 0.1% Tacrolimus Ointment in Segmental Vitiligo: An Open-label Study. 61
32308788 2020
193
Comparison of the efficacy of Tacrolimus 0.1% ointment and Tacrolimus 0.1% plus topical pseudocatalase/superoxide dismutase gel in children with limited vitiligo: a randomized controlled trial. 61
32048900 2020
194
Rituximab treatment for dermatitis herpetiformis in the setting of type 1 diabetes mellitus, celiac disease, vitiligo, autoimmune hemolytic anemia, and autoimmune thrombocytopenia. 61
32016156 2020
195
Psoralen and narrowband UVB combination provides higher efficacy in treating vitiligo compared with narrowband UVB alone: A randomised clinical trial. 61
31651037 2020
196
ΜicroRNA‑421 participates in vitiligo development through regulating human melanocyte survival by targeting receptor‑interacting serine/threonine kinase 1. 61
31974624 2020
197
Activated NLR family pyrin domain containing 3 (NLRP3) inflammasome in keratinocytes promotes cutaneous T-cell response in patients with vitiligo. 61
31756352 2020
198
ATP-P2X7-Induced Inflammasome Activation Contributes to Melanocyte Death and CD8+ T-Cell Trafficking to the Skin in Vitiligo. 61
32035094 2020
199
Identification of CD49a+ CD8+ resident memory T cells in vitiligo-like lesions associated with nivolumab treatment for melanoma. 61
31571305 2020
200
The efficacy and safety of tacrolimus as mono- and adjunctive therapy for vitiligo: A systematic review of randomised clinical trials. 61
31267534 2020
201
Treatment of refractory vitiligo with the 308-nm excimer lamp - An Australian prospective analysis of clinical efficacy and safety. 61